The study compared the functionality of the HER2/neu receptor in the cancer cells of breast and ovarian cancer tissue. Supported by the Austrian Science Fund FWF, the team of scientists involved have shown that the cellular process regulated by this receptor vary greatly between different cancer types. As HER2/neu is the target of successful breast cancer therapy, this result is of major significance for the treatment of ovarian cancer.
Breast and ovarian cancers can both be hereditary, can both be traced back to the same genetic defect and consequently can both possess a large number of HER2/neu receptors. Why therefore do both cancer types not react in the same way when this receptor is blocked? An approach that has proved to be the biggest success of the past 20 years in the treatment of breast cancer has proved unsuccessful in therapies for ovarian cancer. Dr. Dietmar Pils, a member of the laboratory headed by Prof. Michael Krainer, an oncologist at the Department of Internal Medicine I, Medical University of Vienna, has achieved a major breakthrough in finding an answer to this puzzling question.
One Receptor. Two Effects.
The team compared tissue samples from 148 ovarian cancers with results from breast cancer tissue samples and the available patient data. This comparison uncovered interesting differences between the two tissue types. While around 25% of ovarian cancer samples also exhibited a high occurrence of the HER2/neu receptor (a known fact), a different signal molecule (CXCR4) was unaffected in the ovarian cancer tissue. However, breast cancer cells, which exhibit elevated levels of HER2/neu, also produce greater amounts of CXCR4 than healthy cells. The CXCR4 molecule has been linked to the formation of metastases and it is assumed that HER2/neu induces the formation of CXCR4 while simultaneously protecting the molecule against degradation caused by enzymes, thus enabling the cancer to become more aggressive (i.e. metastasising). The results from the Medical University of Vienna now show that the signalling effect produced by HER/2neu is not involved in ovarian cancer.
Molecular Diagnostics Optimise Therapy
Prof. Krainer on the significance of these results: "For almost ten years we have been able to identify hereditary breast cancer using molecular diagnostics and rely on monoclonal antibodies for therapy. The first antibody to be approved for use as a medicine blocks precisely the HER2/neu receptor, thus impeding the cancer’s growth. This is a perfect example of a tailor-made approach to therapy. Our work now reveals just how important it is to carry this differentiation further forward in the development of cancer therapies. After all, in the case of ovarian cancer cells, although the same monoclonal antibody fits this receptor, it has little effect. My laboratory is using findings such as these to create a basis for optimizing the treatment of cancer and to discover where therapies are going wrong. We are very grateful for the support we have received from the FWF, particularly since the potential – including the financial potential – that fundamental research offers for the health system seems not to have been fully recognized yet."
This study, supported by the FWF Austrian Science Fund, clearly demonstrates just how important results from fundamental research can be for state-of-the-art cancer therapy. Furthermore, studies such as this also enable health professionals to choose the optimum treatment for each individual patient from a vast range of therapies. After all, there is no one-size-fits-all treatment for cancer.
Till C. Jelitto | alfa
Not of Divided Mind
19.01.2017 | Hertie-Institut für klinische Hirnforschung (HIH)
CRISPR meets single-cell sequencing in new screening method
19.01.2017 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
19.01.2017 | Earth Sciences
19.01.2017 | Life Sciences
19.01.2017 | Physics and Astronomy